Literature DB >> 29348189

Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes.

Thu H Truong1, Hsiangyu Hu1, Nuri A Temiz2, Kyla M Hagen1, Brian J Girard1, Nicholas J Brady1, Kathryn L Schwertfeger3, Carol A Lange4,5, Julie H Ostrander4.   

Abstract

Proline, glutamic acid, leucine-rich protein 1 (PELP1) is overexpressed in approximately 80% of invasive breast tumors. PELP1 dynamically shuttles between the nucleus and cytoplasm, but is primarily nuclear in normal breast tissue. However, altered localization of PELP1 to the cytoplasm is an oncogenic event that promotes breast cancer initiation and progression. Herein, interacting partners unique to cytoplasmic PELP1 and the mechanisms by which these interactions promote oncogenic PELP1 signaling were sought. AIB1 (amplified in breast cancer 1; also known as SRC-3 or NCOA3) was identified as a novel binding partner of cytoplasmic PELP1 in both estrogen receptor-positive (ER+) and ER-negative cell lines. Cytoplasmic PELP1 expression elevated basal phosphorylation levels (i.e., activation) of AIB1 at Thr24, enhanced ALDH+ tumorsphere formation, and upregulated specific target genes independently of hormone stimulation. Direct manipulation of AIB1 levels using shRNA abrogated cytoplasmic PELP1-induced tumorsphere formation and downregulated cytoplasmic PELP1-specific target genes. SI-2, an AIB1 inhibitor, limited the PELP1/AIB1 interaction and decreased cytoplasmic PELP1-induced tumorsphere formation. Similar results were observed in a murine-derived MMTV-AIB1 tumor cell line. Furthermore, in vivo syngeneic tumor studies revealed that PELP1 knockdown resulted in increased survival of tumor-bearing mice as compared with mice injected with control cells.Implications: These data demonstrate that cytoplasmic PELP1/AIB1-containing complexes function to promote advanced cancer phenotypes, including outgrowth of stem-like cells, associated with estrogen-independent breast cancer progression. Mol Cancer Res; 16(4); 707-19. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29348189      PMCID: PMC5882512          DOI: 10.1158/1541-7786.MCR-17-0598

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  51 in total

1.  Targeting the AIB1 oncogene through mammalian target of rapamycin inhibition in the mammary gland.

Authors:  Maria I Torres-Arzayus; Jing Yuan; Jamie L DellaGatta; Heidi Lane; Andrew L Kung; Myles Brown
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

2.  PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.

Authors:  Valerie Cortez; Cathy Samayoa; Andrea Zamora; Lizatte Martinez; Rajeshwar R Tekmal; Ratna K Vadlamudi
Journal:  Cancer Res       Date:  2014-11-06       Impact factor: 12.701

3.  AIB1 is required for the acquisition of epithelial growth factor receptor-mediated tamoxifen resistance in breast cancer cells.

Authors:  Wenhui Zhao; Qingyuan Zhang; Xinmei Kang; Shi Jin; Changjie Lou
Journal:  Biochem Biophys Res Commun       Date:  2009-01-29       Impact factor: 3.575

4.  Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.

Authors:  Marion E Meijer-van Gelder; Maxime P Look; Harry A Peters; Manfred Schmitt; Nils Brünner; Nadia Harbeck; Jan G M Klijn; John A Foekens
Journal:  Cancer Res       Date:  2004-07-01       Impact factor: 12.701

5.  Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase.

Authors:  S Kato; H Endoh; Y Masuhiro; T Kitamoto; S Uchiyama; H Sasaki; S Masushige; Y Gotoh; E Nishida; H Kawashima; D Metzger; P Chambon
Journal:  Science       Date:  1995-12-01       Impact factor: 47.728

6.  ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance.

Authors:  Maggie C Louie; June X Zou; Alina Rabinovich; Hong-Wu Chen
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

7.  Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer.

Authors:  Valerie Cortez; Monica Mann; Seshidhar Tekmal; Takayoshi Suzuki; Naoki Miyata; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Anil K Sood; Ratna K Vadlamudi
Journal:  Breast Cancer Res       Date:  2012-07-19       Impact factor: 6.466

8.  The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.

Authors:  Hany Onsy Habashy; Desmond G Powe; Emad A Rakha; Graham Ball; R Douglas Macmillan; Andrew R Green; Ian O Ellis
Journal:  Breast Cancer Res Treat       Date:  2009-06-03       Impact factor: 4.872

9.  Progesterone receptor-B enhances estrogen responsiveness of breast cancer cells via scaffolding PELP1- and estrogen receptor-containing transcription complexes.

Authors:  A R Daniel; A L Gaviglio; T P Knutson; J H Ostrander; A B D'Assoro; P Ravindranathan; Y Peng; G V Raj; D Yee; C A Lange
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

10.  De novo HAPLN1 expression hallmarks Wnt-induced stem cell and fibrogenic networks leading to aggressive human hepatocellular carcinomas.

Authors:  Sihem Mebarki; Romain Désert; Laurent Sulpice; Marie Sicard; Mireille Desille; Frédéric Canal; Hélène Dubois-Pot Schneider; Damien Bergeat; Bruno Turlin; Pascale Bellaud; Elise Lavergne; Rémy Le Guével; Anne Corlu; Christine Perret; Cédric Coulouarn; Bruno Clément; Orlando Musso
Journal:  Oncotarget       Date:  2016-06-28
View more
  11 in total

Review 1.  Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies.

Authors:  Ozge Saatci; Kim-Tuyen Huynh-Dam; Ozgur Sahin
Journal:  J Mol Med (Berl)       Date:  2021-10-08       Impact factor: 4.599

2.  Nuclear-localized, iron-bound superoxide dismutase-2 antagonizes epithelial lineage programs to promote stemness of breast cancer cells via a histone demethylase activity.

Authors:  Diego R Coelho; Flavio R Palma; Veronica Paviani; Chenxia He; Jeanne M Danes; Yunping Huang; Juliana C P Calado; Peter C Hart; Cristina M Furdui; Leslie B Poole; Matthew J Schipma; Marcelo G Bonini
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-14       Impact factor: 12.779

3.  Mechanosensitive Steroid Hormone Signaling and Cell Fate.

Authors:  Jason J Northey; Valerie M Weaver
Journal:  Endocrinology       Date:  2022-08-01       Impact factor: 5.051

4.  Role of estrogen receptor coregulators in endocrine resistant breast cancer.

Authors:  Kristin A Altwegg; Ratna K Vadlamudi
Journal:  Explor Target Antitumor Ther       Date:  2021-08-30

Review 5.  90 YEARS OF PROGESTERONE: Steroid receptors as MAPK signaling sensors in breast cancer: let the fates decide.

Authors:  Amy R Dwyer; Thu H Truong; Julie H Ostrander; Carol A Lange
Journal:  J Mol Endocrinol       Date:  2020-07       Impact factor: 5.098

Review 6.  SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.

Authors:  Licen Li; Chu-Xia Deng; Qiang Chen
Journal:  Int J Mol Sci       Date:  2021-04-30       Impact factor: 5.923

7.  Breast Tumor Kinase (Brk/PTK6) Mediates Advanced Cancer Phenotypes via SH2-Domain Dependent Activation of RhoA and Aryl Hydrocarbon Receptor (AhR) Signaling.

Authors:  Amy R Dwyer; Carlos Perez Kerkvliet; Raisa I Krutilina; Hilaire C Playa; Tiffany N Seagroves; Carol A Lange; Deanna N Parke; Warner A Thomas; Branden A Smeester; Branden S Moriarity
Journal:  Mol Cancer Res       Date:  2020-11-10       Impact factor: 6.333

8.  The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.

Authors:  Xingen Wang; Julia Y S Tsang; Michelle A Lee; Yun-Bi Ni; Joanna H Tong; Siu-Ki Chan; Sai-Yin Cheung; Ka Fai To; Gary M Tse
Journal:  Cancer Res Treat       Date:  2018-08-23       Impact factor: 4.679

Review 9.  Stress sensing within the breast tumor microenvironment: how glucocorticoid receptors live in the moment.

Authors:  Carlos Perez Kerkvliet; Thu H Truong; Julie Hanson Ostrander; Carol A Lange
Journal:  Essays Biochem       Date:  2021-12-17       Impact factor: 8.000

10.  PELP1/SRC-3-dependent regulation of metabolic PFKFB kinases drives therapy resistant ER+ breast cancer.

Authors:  Carol A Lange; Julie H Ostrander; Thu H Truong; Elizabeth A Benner; Kyla M Hagen; Nuri A Temiz; Carlos Perez Kerkvliet; Ying Wang; Emilio Cortes-Sanchez; Chieh-Hsiang Yang; Marygrace C Trousdell; Thomas Pengo; Katrin P Guillen; Bryan E Welm; Camila O Dos Santos; Sucheta Telang
Journal:  Oncogene       Date:  2021-06-08       Impact factor: 8.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.